These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38485582)

  • 1. Dysregulation in CD39/CD73 Axis May Trigger the Upsurge of the Immune Suppressive Agent Adenosine in OSA Patients.
    Díaz-García E; García-Sánchez A; Alfaro E; López-Fernández C; Mañas E; Casitas R; Vega S; Cano-Pumarega I; García-Río F; Cubillos-Zapata C
    Arch Bronconeumol; 2024 Apr; 60(4):207-214. PubMed ID: 38485582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
    Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
    Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated CD39+T-Regulatory Cells and Reduced Levels of Adenosine Indicate a Role for Tolerogenic Signals in the Progression from Moderate to Severe COVID-19.
    Elsaghir A; El-Sabaa EMW; Zahran AM; Mandour SA; Salama EH; Aboulfotuh S; El-Morshedy RM; Tocci S; Mandour AM; Ali WE; Abdel-Wahid L; Sayed IM; El-Mokhtar MA
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
    Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
    Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
    Steingold JM; Hatfield SM
    Front Immunol; 2020; 11():570041. PubMed ID: 33117358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
    Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
    Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
    Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
    Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSGL-1: a novel immune checkpoint driving T-cell dysfunction in obstructive sleep apnea.
    Díaz-García E; García-Sánchez A; Alfaro E; López-Fernández C; Mañas E; Cano-Pumarega I; López-Collazo E; García-Río F; Cubillos-Zapata C
    Front Immunol; 2023; 14():1277551. PubMed ID: 37854605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD39/CD73 Dysregulation of Adenosine Metabolism Increases Decidual Natural Killer Cell Cytotoxicity: Implications in Unexplained Recurrent Spontaneous Abortion.
    Zhu J; Song G; Zhou X; Han TL; Yu X; Chen H; Mansell T; Novakovic B; Baker PN; Cannon RD; Saffery R; Chen C; Zhang H
    Front Immunol; 2022; 13():813218. PubMed ID: 35222389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
    Bönner F; Borg N; Burghoff S; Schrader J
    PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased CD73+ Double-Negative T Cells and Elevated Level of Soluble CD73 Correlated With and Predicted Poor Immune Reconstitution in HIV-Infected Patients After Antiretroviral Therapy.
    Wang X; Zhang L; Du J; Wei Y; Wang D; Song C; Chen D; Li B; Jiang M; Zhang M; Zhao H; Kong Y
    Front Immunol; 2022; 13():869286. PubMed ID: 35444646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
    Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
    Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
    Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
    J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.
    Horenstein AL; Chillemi A; Zini R; Quarona V; Bianchi N; Manfredini R; Gambari R; Malavasi F; Ferrari D
    Front Pharmacol; 2018; 9():196. PubMed ID: 29731713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the CD39-CD73-adenosine pathway in liver disease.
    Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
    J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
    Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
    Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
    Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
    Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S
    Blood; 2011 Dec; 118(23):6141-52. PubMed ID: 21998208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.